- Sarepta and FDA will continue dialogue on next steps in the safety labeling process and risk-mitigation approach for non-ambulatory patients Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback